High interobserver variability exists in grading appendiceal goblet cell adenocarcinoma using World Health Organization 5th edition criteria [0.03%]
采用WHO第五版标准分级阑尾杯状细胞癌存在较高的观察者间变异
Lidiane Vieira Marins,Raphiel Murden,Joseph Misdraji et al.
Lidiane Vieira Marins et al.
Aims: Appendiceal goblet cell adenocarcinoma (GCA) is an uncommon malignancy that has been described under various names and grading schemes. The 5th Edition of the World Health Organization (WHO) Classification of Digest...
The prognostic value of tumour budding for survival in stage II and III colorectal cancer: a systematic review and meta-analysis [0.03%]
肿瘤芽生对II期和III期结直肠癌患者生存预后的预测价值：系统评价和 Meta 分析
Yao Shu,Heng Zhang,Alessandro Lugli et al.
Yao Shu et al.
Aims: Tumour budding (TB) has been recognized as an additional prognostic factor in the TNM (2017) and WHO (2019) classification systems. However, its prognostic impact in stages II and III colorectal cancer (CRC) remains...
Aberrant p53 overexpression in benign colon biopsies may predict dysplasia risk in patients with primary sclerosing cholangitis and inflammatory bowel disease [0.03%]
原发性硬化性胆管炎和炎症性肠病患者结肠活检中p53异常过度表达可能预示不典型增生风险
Jonathan D Louie,Gregory Y Lauwers,Won-Tak Choi
Jonathan D Louie
Aims: Patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), collectively termed PSC-IBD, have an increased risk of developing nonconventional and/or invisible colorectal dysplasia, parti...
Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel (DEPP) [0.03%]
荷兰食管病理学小组（DEPP）巴雷特食管p53免疫组化的诊断价值和重复性研究结果
Ylva A Weeda,Sarah M Issa,Hans Halfwerk et al.
Ylva A Weeda et al.
Introduction: Evidence supporting the use of p53 immunohistochemistry (p53-IHC) in Barrett's oesophagus (BE) is largely based on selected series, limiting generalizability. This study evaluates p53-IHC in a nationwide, re...
Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer [0.03%]
短期新辅助内分泌治疗对雌激素受体阳性、HER2阴性乳腺癌肿瘤形态及免疫组化特征的影响
Claudia Grosse,Alexandra Grosse,Petar Noack et al.
Claudia Grosse et al.
Aims: Short-term preoperative endocrine therapy (ET) is increasingly used in oestrogen receptor (ER)-positive, HER2-negative breast cancer as a functional test of endocrine sensitivity. We aimed to characterise histomorph...
Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in lung adenocarcinoma (LUAD) [0.03%]
基于下一代测序的TP53突变状态与肺腺癌（LUAD）中p53免疫染色模式的相关性评估
Yingying Zhang,Ke Zheng,Yuan Tang et al.
Yingying Zhang et al.
Objectives: TP53 mutations, prevalent in 50%-70% of lung adenocarcinoma (LUAD), are associated with poor prognosis and therapeutic resistance. This study aimed to evaluate the diagnostic accuracy of p53 immunohistochemist...
Clinicopathological and molecular features of uterine smooth muscle tumours in patients with Li-Fraumeni syndrome [0.03%]
利-弗拉姆尼综合征患者的子宫平滑肌肿瘤的临床病理和分子特征
Lawrence H Lin,Igor Odintsov,Emily A Towery et al.
Lawrence H Lin et al.
Aims: Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome characterized by germline TP53 mutations and increased risk of various malignancies. While rare uterine leiomyosarcomas (LMS) have been reported, other ...
Clinicopathological and molecular study of two unique cases with microglandular and acinic cell-like breast carcinoma [0.03%]
微小腺体和浆液性细胞样乳腺癌的临床病理和分子研究
Liu Liu,Yong Huang,Shidong Jia et al.
Liu Liu et al.
Metastatic BRAF-mutated, mismatch repair proficient colorectal carcinoma with serrated features mimicking primary intrahepatic cholangiocarcinoma [0.03%]
具错配修复完全型肠嗜黏膜特征的转移性BRAF突变结直肠癌伴肝内胆管细胞癌样表现
Adrian C Bateman,Krithika Elangovan,Elena Papadakou et al.
Adrian C Bateman et al.
Lineage infidelity in a CD30-positive large B-cell lymphoma with phenotypic drift [0.03%]
具有表型漂移的CD30阳性大B细胞淋巴瘤中的系谱不忠fulness
Juliette Beaucarne,Anne-Laure Trepant,Stéphanie d&#x;Otreppe et al.
Juliette Beaucarne et al.